<DOC>
	<DOCNO>NCT00658021</DOCNO>
	<brief_summary>The primary objective study test hypothesis glycemic control , measure change hemoglobin A1c ( HbA1c ) baseline endpoint , exenatide superior placebo 28 week treatment adolescent patient type 2 diabetes naïve antidiabetes agent , patient treat metformin , SU , combination metformin SU .</brief_summary>
	<brief_title>Safety Efficacy Exenatide Monotherapy Adjunctive Therapy Oral Antidiabetic Agents Adolescents With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>Inclusion Criteriapatients eligible include study meet follow criterion : male female age 10 17 year , inclusive . The number patient ≥17 year age limit 10 % patient treatment arm history type 2 diabetes original diagnosis base least one American Diabetes Association ( ADA ) diagnostic criterion treat metformin , SU , metformin SU ( without diet exercise ) , least 3 month naïve antidiabetes agent treat diet exercise alone . The dose oral agent ( ) stable 30 day prior screen visit fast Cpeptide &gt; 0.6 ng/mL HbA1c 6.5 % 10.5 % , inclusive . Disease Diagnostic Criteriafor purpose study , patient type 2 diabetes define : diagnosis type 2 diabetes , determine ADA diagnostic criterion antibody testing , document confirmed patient 's medical record , include laboratory determination consistent one follow patient 's medical history fast blood glucose 126 mg/dL ( 7.0 mmol/L ) random blood glucose 200 mg/dL ( 11.1 mmol/L ) twohour OGTT ( Oral Glucose Tolerance Test ) ≥ 200 mg/dL ( 11.1 mmol/L ) AND one following : antibody GAD65 OR antibodies islet cell antigen ( ICA512 ) . Exclusion Criteriapatients exclude study meet follow criterion : previously expose exenatide , complete withdrawn study study investigate exenatide unwilling unable inject study medication currently use inhaled steroid dose equal 1000g Flovent ( fluticasone propionate ) daily use oral steroid within last 60 day 20 day use within past year use weight loss medication ( ) within 30 day screen used insulin 10 week 3 month prior screen history renal disease , serum creatinine &gt; 1.6 mg/dL ( 141.4 µmol/L ) ( male ) &gt; 1.4 mg/dL ( 123.8 µmol/L ) ( female ) hepatic dysfunction , define aspartate ( AST ) alanine ( ALT ) transaminase &gt; 3.0 time upper limit normal ( ULN ) .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>diabetes</keyword>
	<keyword>adolescent</keyword>
	<keyword>exenatide</keyword>
	<keyword>Astra Zeneca</keyword>
</DOC>